Abstract
IntroductionThe use of immune checkpoint inhibitors (ICIs) is rapidly expanding in cancer treatment. ICIs have a unique safety profile, characterised by immune-related adverse events (irAEs). The safety profile of ICIs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have